Диссертация (1139510), страница 52
Текст из файла (страница 52)
J Clin Psychiatry 2001;62 (suppl 22).146. Greenberg PE, Kessler RC, Birnbaum HG, et al. The economic burden ofdepression in the United States: how did it change between 1990 and 2000? J ClinPsychiatry 2003;64:1465—75.147. Grigoriadis S, Robinson GE. Gender issues in depression. Ann ClinPsychiatry. 2007;19:247–255.148. Hajek T, Kozeny J, Kopecek M, et al.: Reduced subgenual cingulatevolumes in mood disorders: a meta-analysis. J Psychiatry Neurosci 2008, 33:91–99.149. Hardeveld F, Spijker J, De Graaf R et al. Prevalence and predictors ofrecurrence of major depressive disorder in the adult population. Acta PsychiatrScand 2010;122:184–91.150. Hardeveld F, Spijker J, De Graaf R et al. Recurrence of major depressivedisorder and its predictors in the general population: results from the NetherlandsMental Health Survey and Incidence Study (NEMESIS).
PsycholMed 2013;43:39–48.151. Hek K, Demirkan A, Lahti J, Terracciano A. A genome-wide associationstudy of depressive symptoms. Biol Psychiatry. 2013;73:667–78.152. Hicks J, Bishop J, Sangkuhl K, et al. Clinical PharmacogeneticsImplementationConsortium(CPIC)Guidelinefor CYP2D6 and CYP2C19 Genotypes and Dosing of Selective SerotoninReuptake Inhibitors. Clinical Pharmacology and Therapeutics. 2015;98(2):127134.153. Hirschfeld RM, Russell JM, Delgado PL, et al.
Predictors of response toacute treatment of chronic and double depression with sertraline or imipramine. JClin Psychiatry. 1998;59:669-675.154. Hong CJ, Chen TJ, Yu YW, et al. Response to fluoxetine and serotonin 1Areceptor (C-1019G) polymorphism in Taiwan Chinese major depressive disorder.Pharmacogenomics J. 2006;6:27–33.155. http://www.cypalleles.ki.se156. http://www.cypalleles.ki.se/cyp2c19.htm157. http://www.who.int/mediacentre/factsheets/fs369/ru/index.html158. http://www.who.int/mental_health/management/depression/who_paper_depression_wfmh_2012.pdf159. https://www.ncbi.nlm.nih.gov/projects/SNP/.160. https://www.snpedia.com/index.php/DbSNP.280161. Huezo-Diaz P, Uher R, Smith R, Rietschel M, Henigsberg N, Marusic A,Mors O, Maier W, Hauser J, Souery D, Placentino A, Zobel A, Larsen ER, CzerskiPM, Gupta B, Hoda F, Perroud N, Farmer A, Craig I, Aitchison KJ, McGuffin P.Moderation of antidepressant response by the serotonin transporter gene.
Br JPsychiatry. 2009 Jul;195(1):30-8162. Ilyas S, Moncrieff J (2012) Trends in prescriptions and costs of drugs formental disorders in England, 1998–2010. Br J Psychiatry 200(5):393–398163. Inder WJ, Prickett TC, Mulder RT, et al. Reduction in basal afternoonplasma ACTH during early treatment of depression with fluoxetine.Psychopharmacology (Berl). 2001 Jun;156(1):73-8.164.
Ingelman-Sundberg M. Genetic polymorphisms of cytochrome P450 2D6(CYP2D6): clinical consequences, evolutionary aspects and functional diversity.Pharmacogenomics J. 2005;5(1):6-13.165. International Statistical Classification of Diseases and Related HealthProblems10thRevision.http://apps.who.int/classifications/icd10/browse/2010/en#/F30-F39166. Ionescu DF, Papakostas GI. Experimental medication treatment approachesfor depression. Transl Psychiatry (2017) 7, e1068; doi:10.1038/tp.2017.33167. Ionescu DF, Rosenbaum JF, Alpert JE. Pharmacological approaches to thechallenge of treatment-resistant depression.
Dialogues Clin Neurosci 2015;17:111–126.168. Jakobsen JC, Katakam KK, Schou A, Hellmuth SG, Stallknecht SE, et al.Selective serotonin reuptake inhibitors versus placebo in patients with majordepressive disorder. A systematic review with meta-analysis and Trial SequentialAnalysis. BMC Psychiatry. 2017;17:58.169. Jang KL, Livesley WJ, Taylor S, Stein MB, Moon EC. Heritability ofindividual depressive symptoms. J Affect Disord. 2004;80:125–33.170. Jani BD, McLean G, Nicholl BI, et al.
Risk assessment and predictingoutcomes in patients with depressive symptoms: a review of potential role ofperipheral blood based biomarkers. Front Hum Neurosci. 2015;9:18.171. Joffe RT, Regan JJ. Personality and response to tricyclic antidepressants indepressed patients. J Nerv Ment Dis. 1989;177:745-749.172. Johnson CF, Williams B et al. ‘Doing the right thing’: factors influencingGP prescribing of antidepressants and prescribed doses.
BMC Family Practice(2017) 18:72.173. Jorm AF, Patten SB, Brugha TS, Mojtabai R. Has increased provision oftreatment reduced the prevalence of common mental disorders? Review of theevidence from four countries. World Psychiatry. 2017;16(1):90-99.281174. Joyce PR, Mulder RT, Cloninger CR. Temperament predicts clomipramineand desipramine response in major depression. J Affect Disord.
1994;30:35-46.175. Jureidini J, Tonkin A. Overuse of antidepressant drugs for the treatment ofdepression. CNS Drugs. 2006;20(8):623–32.176. Kamijima K, Higuchi T, Ishigooka J. Aripiprazole augmentation toantidepressant therapy in Japanese patients with major depressive disorder: Arandomized, double-blind, placebo-controlled study (ADMIRE study). Journal ofAffective Disorders 151 (2013) 899–905177. Kang A.M., Palmatier M.A., Kidd K.K. Global Variation of a 40-bp VNTRin the 3’-Untranslated Region of the Dopamine Transporter Gene (SLC6A3).BIOL PSYCHIATRY 1999;46:151–160.178. Kantor ED, Rehm CD, Haas JS, Chan AT, Giovannucci EL.
Trends inprescription drug use among adults in the united states from 19992012. JAMA. 2015;314:1818–1830.179. Kapur S, Phillips AG, Insel TR. Why has it taken so long for biologicalpsychiatry to develop clinical tests and what to do about it? Mol Psychiatry.2012;17:1174–9.180. Karger A. Gender differences in depression.
BundesgesundheitsblattGesundheitsforschung Gesundheitsschutz. 2014; 57(9):1092–1098.181. Kato M, Fukuda T, Wakeno M, et al. Effects of the serotonin type 2A, 3Aand 3B receptor and the serotonin transporter genes on paroxetine and fluvoxamineefficacy and adverse drug reactions in depressed Japanese patients.Neuropsychobiology. 2006;53:186–95.182. Kato M, Serretti A. Review and meta-analysis of antidepressantpharmacogenetic findings in major depressive disorder.
Molecular Psychiatry(2010) 15, 473–500.183. Katona CL , Abou-Saleh MT , Harrison DA , Nairac BA , Edwards DR ,Lock T , et al . 1995 . Placebo-controlled trial of lithium augmentation of fluoxetine and lofepramine . Br J Psychiatry 166 : 80 – 86.184. Keitner GI , Garlow SJ , Ryan CE , Ninan PT , Solomon DA , Nemeroff CB, et al .
2009 . A randomized, placebo-controlled trial of risperidone augmentationfor patients with diffi cult-totreat unipolar, non-psychotic major depression . JPsychiatr Res 43 : 205 – 214 .185. Keitner GI, Ryan CE, Miller IW, Norman WH: Recovery and majordepression: factors associated with twelve-month outcome. Am J Psychiatry 1992,149:93–99.186. Kemp, A.H., Gordon, E., Rush, J., Leanne, M., Williams, M., 2008.Improving the prediction of treatment response in depression: integration of282clinical, cognitive, psychophysiological, neuroimaging and genetic measures. CNSSpectr.
13, 1066–1086.187. Kendler, Kenneth S, Kuhn, J., & Prescott, C. A. (2004). The interrelationshipof neuroticism, sex, and stressful life events in the prediction of episodes of majordepression. The American journal of psychiatry, 161(4), 631–6.188. Kendler, Kenneth S, Myers, J., & Prescott, C.
A. (2005). Sex differences inthe relationship between social support and risk for major depression: alongitudinal study of opposite-sex twin pairs. The American journal of psychiatry,162(2), 250–6.189. Kennedy SH, Lam RW, McIntyre RS, et al. Canadian Network for Moodand Anxiety Treatments (CANMAT) 2016 Clinical Guidelines for theManagement of Adults with Major Depressive Disorder: Section 3.Pharmacological Treatments. Can J Psychiatry. 2016;61(9):540-60.190. Kessing LV, Hansen MG, Andersen PK et al. The predictive effect ofepisodes on the risk of recurrence in depressive and bipolar disorders—a life-longperspective. Acta Psychiatr Scand 2004;109:339–44.191. Kessler RC, McGonagle KA, Swartz M, et al.
Sex and depression in theNational Comorbidity Survey. I: Lifetime prevalence, chronicity and recurrence. JAffect Disord. 1993;29:85-96.192. Kessler RC, Walters EE. Epidemiology of DSM-III-R major depression andminor depression among adolescents and young adults in the National ComorbiditySurvey.
Depress Anxiety. 1998; 7(1):3-14.193. Kessler RC, Zhao S, Blazer DG, Swartz M. Prevalence, correlates, andcourse of minor depression and major depression in the National ComorbiditySurvey. J Affect Disord. 1997 Aug; 45(1-2):19-30.194. Khan A, Brown WA. Antidepressants versus placebo in major depression:an overview. World Psychiatry. 2015;14:294–300.195. Kim DK, Lim SW, Lee S, et al.
Serotonin transporter gene polymorphismand antidepressant response. Neuroreport. 2000;11:215–9196. Kim H, Lim SW, Kim S, et al. Monoamine transporter gene polymorphismsand antidepressant response in koreans with late-life depression. JAMA.2006;296:1609–18197. Kirchheiner J, Brøsen K, Dahl ML, Gram LF, Kasper S, Roots I, Sjöqvist F,Spina E, Brockmöller. CYP2D6 and CYP2C19 genotype-based doserecommendations for antidepressants: a first step towards subpopulation-specificdosages. J Acta Psychiatr Scand.
![](https://s.studizba.com/z.php?f=/templates/si/i/noavatar.png&w=100&h=100&t=1"){kind=avatar}
